This guideline addresses major issues related to cholesterol management and primary ASCVD prevention, which are also addressed in the recently published 2018 Cholesterol Clinical Practice Guidelines.S4.3-1 There- fore, the relevant subset of those recommendations is presented here, along with its accompanying sup- portive text. This writing committee agrees that for young adults (20 to 39 years of age), priority should be given to estimating lifetime risk and promoting a healthy lifestyle. Only in select patients with mod- erately high LDL-C ( 160 mg/dL) or those with very high LDL-C ( 190 mg/dL) is drug therapy indicated. In adults 40 to 75 years of age, 10-year ASCVD risk should guide therapeutic considerations. The higher the estimated risk, the more likely the patient is to benefit from statin treatment. For patients >75 years of age, assessment of risk status and a clinician pa- tient risk discussion are needed to decide whether to continue or initiate statin treatment. For a detailed discussion of statin safety and management of statin- associated side effects, please refer to Section 5 of the 2018 Cholesterol Clinical Practice Guidelines.S4.3-1 Recommendation-Specific Supportive Text 1. Large-scale RCTs in primary prevention dem- onstrated ASCVD risk reduction with moder- and high-intensity statin that outweighed the observable risks. Subsequently, a large-scale RCT in an eth- nically and racially diverse population confirmed statin benefit from a moderate-intensity statin therapy, as compared with placebo, in interme- diate-risk patients. That RCT enrolled men 55 years of age and women 65 years of age with at least 1 cardiovascular risk factor. In the placebo Figure 3. Primary prevention. Colors correspond to Class of Recommendation in Table 1. 